Evogene (NASDAQ: EVGN) reported Q3 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $311 thousand versus the consensus estimate of $270 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.